SCHEMBL48464

SCHEMBL48464

CCOC(=O)CNC(=O)Nc1nc(C)c(-c2ccc(S(=O)(=O)N(C)C)cc2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
NPSR1 Q6W5P4 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RXFP1 Q9HBX9 2/20 0.53
PIK3CD O00329 5/20 0.49
PIK3CA P42336 5/20 0.49
PIK3CB P42338 5/20 0.49
PIK3CG P48736 5/20 0.49
PI4KB Q9UBF8 3/20 0.46
KDM4E B2RXH2 5/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 3/20 0.44
MMP3 P08254 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48676 0.90 PIK3CD (0.53) ALDH1A1NPSR1SMN1; SMN2RXFP1PIK3CD
SCHEMBL48491 0.89 PIK3CD (0.64) ALDH1A1NPSR1RXFP1PIK3CDPIK3CA
SCHEMBL48672 0.88 PIK3CD (0.53) ALDH1A1NPSR1SMN1; SMN2RXFP1PIK3CD
SCHEMBL1890819 0.82 PPID (0.55) ALDH1A1NPSR1SMN1; SMN2RXFP1PIK3CD
SCHEMBL48699 0.82 PIK3CD (0.54) ALDH1A1NPSR1SMN1; SMN2RXFP1PIK3CD
SCHEMBL48569 0.80 PIK3CG (0.75) ALDH1A1NPSR1SMN1; SMN2RXFP1PIK3CD
SCHEMBL48519 0.79 PIK3CD (0.61) ALDH1A1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1784035 0.78 PIK3CD (0.63) PIK3CDPIK3CAPIK3CBPIK3CGPI4KB
SCHEMBL48850 0.76 PIK3CD (0.69) PIK3CDPIK3CAPIK3CBPIK3CGPI4KB
SCHEMBL48623 0.76 PIK3CD (0.72) SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B ALDH1A1 3271/4885NPSR1 2644/4885SMN1; SMN2 2920/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B ALDH1A1 3271/4885NPSR1 2644/4885SMN1; SMN2 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.